


**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (Extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).



RECEIVED

MAY 22 2003

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821-1.825 for the following reason(s):

TECH CENTER 1600/2000

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Seqs in Figures 5 and 6

RECEIVED

MAY 22 2003

**Applicant Must Provide:**

TECH CENTER 1600/2000

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". *if necessary*
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
PatentIn Software Program Support

Technical Assistance.....703-287-0200  
To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**



EN et al.  
S8 08/981,824  
AUTOREACTIVE PEPTIDES FROM HUMAN GLUTAMIC ACID  
DECARBOXYLASE (GAD)  
Docket No. 2923-393

RECEIVED

MAY 22 2003

Patent Application Publication Aug. 22, 2002 Sheet 5 of 6

US 2002/0114816 A1

TECH CENTER 1600/2900

ALPHA CHAIN	TCRAV	N-Region	TCRAJ	
Patient 40 Clone 40/2#20	CAV TGTGCCGTG TCRAV2S1A2	NIA AACATTGCT	GGSGQGNIIF GGCGGAAGCCAAGGAATCTCATCTTT TCRAJ42	SEQ ID NO: 35 SEQ ID NO: 34
Patient 24 Clone 24/31#1/1	CAA TGTGCAGCA TCRAV8S1A1	RAM AGGGCCATG	NRDDKIIF AACAGAGATGACAAGATCATCTTT TCRAJ30	SEQ ID NO: 37 SEQ ID NO: 36
Patient 24 Clone 24/31#1/4	CAA TGTGCAGCA TCRAV8S1A1	RAM AGGGCCATG	NRDDKIIF AACAGAGATGACAAGATCATCTTT TCRAJ30	SEQ ID NO: 37 SEQ ID NO: 36
Patient 24 Clone 24/31#2F7	CAA TGTGCAGCA TCRAV8S1A1	RAM AGGGCCATG	NRDDKIIF AACAGAGATGACAAGATCATCTTT TCRAJ30	SEQ ID NO: 37 SEQ ID NO: 36
Patient 24 Clone 24/31#9	CAA TGTGCAGCA TCRAV8S1A1	RAM AGGGCCATG	NRDDKIIF AACAGAGATGACAAGATCATCTTT TCRAJ30	SEQ ID NO: 37 SEQ ID NO: 36

Fig. 5

RECEIVED

Patent Application Publication Aug. 22, 2002 Sheet 6 of 6

US 2002/0114816 A1 MAY 22 2003

TECH CENTER 1600/2800



BETA CHAIN TCRBV "N-Region" TCRBJ

Patient 40  
Clone 2/20

C S A  
TGCGTGTCT  
TCRBV2S1A1T

S A G W  
AGTGCGGGTTGG

S N Q P Q H F  
AGCAATCAGCCCCAGCATTTT  
TCRBJ1.5

SEQ ID NO: 39  
SEQ ID NO: 39

Patient 24  
Clone 31/1/1

C X S S L D A S G  
TGCKCCAGC AGCTTGGATGCGAGCGGG  
TCRBV5S1A1T

S Y N E Q F F  
AGCTACAATGAGCAGTTCTTC  
TCRBJ

SEQ ID NO: 41  
SEQ ID NO: 40

Patient 24  
Clone 31/1/4

C X S S L D A S G  
TGCKCCAGC AGCTTGGATGCGAGCGGG  
TCRBV5S1A1T

S Y N E Q F F  
AGCTACAATGAGCAGTTCTTC  
TCRBJ

SEQ ID NO: 41  
SEQ ID NO: 40

Patient 24  
Clone 31/PP7

C X S S L D A S G  
TGCKCCAGC AGCTTGGATGCGAGCGGG  
TCRBV5S1A1T

S Y N E Q F F  
AGCTACAATGAGCAGTTCTTC  
TCRBJ

SEQ ID NO: 41  
SEQ ID NO: 40

Patient 24  
Clone 31/9

C X S S L D A S G  
TGCKCCAGC AGCTTGGATGCGAGCGGG  
TCRBV5S1A1T

S Y N E Q F F  
AGCTACAATGAGCAGTTCTTC  
TCRBJ

SEQ ID NO: 41  
SEQ ID NO: 40

Fig. 6